Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8686838 | 1.00 | GRIA2 (0.51) | GRIA2CA12CA2CA9HSP90AA1 | |
| SCHEMBL11689069 | 0.85 | GRIA2 (0.46) | GRIA2CA12CA2CA9HSP90AA1 | |
| SCHEMBL11758539 | 0.85 | GRIA2 (0.46) | GRIA2CA12CA2CA9HSP90AA1 | |
| SCHEMBL7752547 | 0.76 | CA12 (0.56) | GRIA2CA12CA2CA9NPSR1 | |
| SCHEMBL16029847 | 0.69 | GRIA2 (0.46) | GRIA2CA12CA2CA9HSP90AA1 | |
| SCHEMBL4894972 | 0.68 | CA12 (0.56) | GRIA2CA12CA2CA9NPSR1 | |
| SCHEMBL11821726 | 0.64 | CA12 (0.51) | GRIA2CA12CA2CA9NPSR1 | |
| SCHEMBL6197084 | 0.64 | GRIA2 (0.41) | GRIA2CA12CA2CA9NPSR1 | |
| SCHEMBL10574018 | 0.64 | CA12 (0.51) | CA12CA2CA9 | |
| Benzo[C][1,2,5]Oxadiazole 1-Oxide SCHEMBL7574801 | 0.64 | CA12 (0.47) | GRIA2CA12CA2CA9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968713-B2 | Method of synthesizing quinoxaline derivative by microwave irradiation | NIHON UNIVERSITY (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090048445-A1 | Method of Synthesizing Quinoxaline Derivative by Microwave Irradiation | NIHON UNIVERSITY (JP) | 2009-02-19 | — | — | US | disclosed |
| WO-1998027969-A2 | ANTIMICROBIAL PHENAZINE COMPOUNDS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-07-02 | — | — | WO | disclosed |
| US-4001410-A | MICROBIOCIDES AND LIVESTOCK GROWTH PROMOTERS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
| US-3980779-A | ANTIMICROBIAL ACTIVITY | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048445-A1 | Method of Synthesizing Quinoxaline Derivative by Microwave Irradiation | PDXK, PDK2, NQO2 | GRIA2 3439/4885CA12 3268/4885CA2 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.